NRx Pharmaceuticals (NRXPW) Competitors $0.14 +0.04 (+42.28%) As of 10/16/2025 03:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock NRXPW vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Aravive Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity NRx Pharmaceuticals (NASDAQ:NRXPW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations. Does the media prefer NRXPW or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 1.91 beat 180 Life Sciences' score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment NRx Pharmaceuticals Very Positive 180 Life Sciences Neutral Which has stronger earnings & valuation, NRXPW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Is NRXPW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A N/A 180 Life Sciences N/A N/A N/A SummaryNRx Pharmaceuticals and 180 Life Sciences tied by winning 1 of the 2 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXPW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXPW vs. The Competition Export to ExcelMetricNRx PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$223.39M$6.08B$10.55BDividend YieldN/A3.81%5.73%4.78%P/E RatioN/A98.1184.5927.19Price / SalesN/A5,872.30610.53132.96Price / CashN/A13.1937.8662.13Price / BookN/A100.7612.466.65Net IncomeN/A-$90.99M$3.32B$276.79M7 Day Performance2.56%0.46%2.29%1.75%1 Month PerformanceN/A5.77%9.66%5.15%1 Year PerformanceN/A706.08%75.05%36.96% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPWNRx PharmaceuticalsN/A$0.14+42.3%N/A+155.5%$0.00N/A0.00N/APositive NewsGap UpATNFW180 Life SciencesN/A$0.06-11.2%N/A+172.9%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.21-22.2%N/AN/A$0.00$110.87K0.0040Gap DownALVOWAlvotechN/A$1.75+17.4%N/A-51.8%$0.00$560.10M0.004Gap UpHigh Trading VolumeARAVAraviveN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/A+15.3%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.10-1.8%N/A+214.5%$0.00$39.19M0.0070BTMDWbioteN/A$0.01-15.8%N/A-98.7%$0.00$199.07M0.00N/AHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.06+16.2%N/A-82.1%$0.00N/A0.008Positive NewsShort Interest ↑High Trading VolumeCELUWCelularityN/A$0.03-5.1%N/A+133.8%$0.00$44.59M0.00220Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Ainos Competitors Alvotech Competitors Aravive Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Celularity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXPW) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
